There is no strict clinical definition of short-term GLP-1 use, and duration will depend on individual goals, tolerability, rate of progress, and prescriber guidance
West CA, He C, Su M, Swanson SJ, Mentzer SJ
A thorough initial consultation to assess your health history, current medications, and appropriateness for peptide therapy Baseline investigations, including relevant blood panels, before commencing any peptide protocol Clear informed consent regarding the experimental nature of these therapies and the limitations of current evidence Sourcing from reputable, TGA-registered compounding pharmacies only Regular review appointments to monitor for any adverse effects and reassess ongoing appropriateness An honest conversation about alternatives --- including proven regenerative therapies such as PRP, physiotherapy, and targeted nutrition --- which may complement or replace peptide use Questions to Ask Your Practitioner If you are thinking about peptide therapy, the following questions will assist in guiding an informed discussion
Learn more about betaine with pepsin here
Eli Lillys oral GLP-1 medication orforglipron is expected to be approved by the FDA early this year, and is expected to retail for $399 per month direct to consumers
In a mouse model of diabetes, topiramate effectively protected the brain from diabetes-induced damage by reducing 4-HNE levels and increasing glutathione (GSH) levels ( However, in a study on the potential toxic effects of topiramate on the liver and kidney of male mice, topiramate significantly decreased the activities of the antioxidant enzymes SOD and CAT, while increasing MDA and NO levels ( In vitro study found that topiramate increased MDA, NO and ROS production in astrocytes, showing a dose-dependent negative effect ( These findings suggest that topiramate may exert dual effects on oxidative stress, offering neuroprotection in certain contexts while exacerbating oxidative stress under different conditions and dosages